Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
October 22, 2019
October 22, 2019 / Press Releases
Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease...
Read More
Presentation: Phase 2 Celiac Disease Data from UEG Week 2019
October 21, 2019
October 21, 2019 / Press Releases
View Presentation Here
Read More
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA
January 10, 2018
January 10, 2018 / Press Releases
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA is designed to enable patients to develop tolerance to gluten...
Read More
Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease
August 21, 2017
August 21, 2017 / Press Releases
Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that its Investigational New Drug (IND) for TIMP-GLIA is now open with the US Food &...
Read More
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease
December 8, 2015
December 8, 2015 / Press Releases
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases Osaka, Japan, December 8, 2015, and Chicago, Ill., December 7, 2015 – Takeda Pharmaceutical Company...
Read More
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis
December 4, 2015
December 4, 2015 / Press Releases
Cour Pharma Presents Scientific Poster on Breakthrough Celiac Treatment at 16th Annual International Celiac Disease Symposium
December 3, 2015
December 3, 2015 / Press Releases
Download Poster Here
Read More
Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease
October 19, 2015
October 19, 2015 / Press Releases
Proprietary Antigen-specific Nanoparticles and Cure for Celiac Disease Chicago (June 22, 2015) – Cour Pharmaceutical Development Company today announced new data from a preclinical live animal study demonstrating a breakthrough...
Read More